WilmerHale Advising AVEO Oncology in Sale to LG Chem

WilmerHale Advising AVEO Oncology in Sale to LG Chem

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
WilmerHale is advising AVEO Oncology on its pending sale to LG Chem in an all-cash transaction with an implied equity value of approximately $566 million. Headquartered in Massachusetts, AVEO Oncology is a biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. In 2021, AVEO Oncology received FDA approval for FOTIVDA® (tivozanib), the first therapy approved for adult patients with relapsed or refractory advanced renal cell carcinoma. 
 
Based in Seoul, South Korea, LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials and life sciences.
 
The WilmerHale team advising AVEO Oncology includes Cynthia Mazareas, Joseph Conahan, JC Minko, Ryan Brewer, Milan Kumar and Virginia Pavlick.

Read more.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel